JP2016501829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501829A5 JP2016501829A5 JP2015531671A JP2015531671A JP2016501829A5 JP 2016501829 A5 JP2016501829 A5 JP 2016501829A5 JP 2015531671 A JP2015531671 A JP 2015531671A JP 2015531671 A JP2015531671 A JP 2015531671A JP 2016501829 A5 JP2016501829 A5 JP 2016501829A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- peptide
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 210000004027 cell Anatomy 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 9
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 230000035699 permeability Effects 0.000 claims 6
- 244000052769 pathogen Species 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 229930186217 Glycolipid Natural products 0.000 claims 2
- 102000004895 Lipoproteins Human genes 0.000 claims 2
- 108090001030 Lipoproteins Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700432P | 2012-09-13 | 2012-09-13 | |
| US61/700,432 | 2012-09-13 | ||
| EP12184311.4 | 2012-09-13 | ||
| EP12184311 | 2012-09-13 | ||
| PCT/IB2013/058497 WO2014041505A1 (en) | 2012-09-13 | 2013-09-12 | Cell penetrating peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501829A JP2016501829A (ja) | 2016-01-21 |
| JP2016501829A5 true JP2016501829A5 (enExample) | 2017-07-06 |
| JP6306593B2 JP6306593B2 (ja) | 2018-04-04 |
Family
ID=46826380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531671A Active JP6306593B2 (ja) | 2012-09-13 | 2013-09-12 | 細胞透過性ペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9657064B2 (enExample) |
| EP (1) | EP2895499B1 (enExample) |
| JP (1) | JP6306593B2 (enExample) |
| KR (1) | KR101861416B1 (enExample) |
| CN (1) | CN104736553B (enExample) |
| AU (1) | AU2013316679B2 (enExample) |
| CA (1) | CA2884677C (enExample) |
| RU (1) | RU2670488C2 (enExample) |
| WO (1) | WO2014041505A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187534B2 (en) * | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| BR112016002721A2 (pt) * | 2013-08-07 | 2018-07-10 | Yeda Research And Development Company Ltd. | peptídeos capazes de reativar p53 mutantes |
| US10131690B2 (en) | 2014-04-25 | 2018-11-20 | Phi Pharma Sa | C6S specific transporter molecules |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| US10316061B2 (en) | 2014-10-02 | 2019-06-11 | Temple University Of The Commonwealth System Of Higher Education | Synthesis of cell penetrating peptides for drug delivery and stem cell applications |
| TWI683668B (zh) * | 2014-12-10 | 2020-02-01 | 華西亞生醫股份有限公司 | 用於免疫作用中有效抗體生産的新穎蛋白質結構 |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| CA3010779A1 (en) * | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| KR101799805B1 (ko) | 2016-04-07 | 2017-11-21 | (주)네오리젠바이오텍 | 세포 투과 펩티드 |
| WO2017176081A1 (ko) * | 2016-04-07 | 2017-10-12 | (주)네오리젠바이오텍 | 세포 투과 펩티드 |
| KR102879364B1 (ko) * | 2016-09-21 | 2025-11-04 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| CN106544351B (zh) * | 2016-12-08 | 2019-09-10 | 江苏省农业科学院 | CRISPR-Cas9体外敲除耐药基因mcr-1的方法及其专用细胞穿透肽 |
| EP3360891B1 (en) | 2017-02-14 | 2022-03-30 | Karlsruher Institut für Technologie | Cell penetrating peptides of human origin |
| US11117930B2 (en) | 2017-02-23 | 2021-09-14 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
| CA3066077A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| CA3073062A1 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| CN108070025B (zh) * | 2017-10-24 | 2019-11-19 | 中山大学附属口腔医院 | 一种细胞穿透肽和细胞穿透肽复合物及二者的应用 |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| BR112021010982A2 (pt) | 2018-12-07 | 2021-08-31 | Oxford University Innovation Limited | Ligantes |
| AU2020207087A1 (en) * | 2019-01-12 | 2021-08-12 | The Methodist Hospital | Self-assembled peptide nanoparticle and use thereof |
| AU2020417604A1 (en) * | 2019-12-31 | 2022-08-11 | Xiamen Innovax Biotech Co., Ltd. | Multimerization delivery system for intracellular delivery of molecule |
| US20230257429A1 (en) * | 2020-07-13 | 2023-08-17 | National University Of Singapore | Peptide adjuvant for its therapeutic applications in viral and tumour vaccine development and cancer immunotherapy and autoimmune disease diagnosis and treatments |
| WO2022079175A1 (en) | 2020-10-14 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
| FR3143031A1 (fr) * | 2022-12-08 | 2024-06-14 | Université Grenoble Alpes | Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles |
| FR3154729B1 (fr) * | 2023-10-25 | 2025-10-24 | Univ Rouen Normandie | Construction comprenant ou constituée d’une séquence peptidique apte à inhiber l’interaction de la filamine A avec le récepteur UT - composition pharmaceutique et produis associés |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| EP1279404A1 (en) * | 2001-07-26 | 2003-01-29 | Istituto Superiore di Sanità | Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
| EP2480568B1 (en) * | 2009-09-23 | 2016-04-20 | Université Paris Descartes | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| EP2563399B1 (fr) * | 2010-04-26 | 2014-06-11 | Université Joseph Fourier | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles |
| DK2608799T3 (en) | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
-
2013
- 2013-09-12 JP JP2015531671A patent/JP6306593B2/ja active Active
- 2013-09-12 KR KR1020157007460A patent/KR101861416B1/ko active Active
- 2013-09-12 EP EP13795574.6A patent/EP2895499B1/en active Active
- 2013-09-12 AU AU2013316679A patent/AU2013316679B2/en active Active
- 2013-09-12 WO PCT/IB2013/058497 patent/WO2014041505A1/en not_active Ceased
- 2013-09-12 CA CA2884677A patent/CA2884677C/en active Active
- 2013-09-12 US US14/427,459 patent/US9657064B2/en active Active
- 2013-09-12 CN CN201380047957.5A patent/CN104736553B/zh active Active
- 2013-09-12 RU RU2015113378A patent/RU2670488C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501829A5 (enExample) | ||
| RU2015113378A (ru) | Новые проникающие в клетку пептиды | |
| Tan et al. | Exosomes as nano-theranostic delivery platforms for gene therapy | |
| JP2018509936A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| AR127118A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| JP2019536426A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2018512856A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| JP2019515650A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| JP2016503655A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| ME03808B (me) | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2018528237A5 (enExample) | ||
| PE20240778A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres | |
| AR110857A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |